Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens

 Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens

Shots:

  • Cardiff University will receive milestone payments that advance from the discovery collaboration into clinical development and royalty payments on sales of any products that reach the market. Ervaxx will fund this program
  • Ervaxx gains an exclusive license to Cardiff University patents claiming T cells and TCRs reactive to cancer-specific antigens and has the right to advance resulting candidate T-cell/TCR-based immunotherapeutics and cancer vaccines
  • Ervaxx Dark Antigens derive from vast untapped expanses of genetic ‘dark matter’, which are generally silenced in normal tissue but can become selectively activated in cancer

Click here ­to­ read full press release/ article | Ref: PR Newswire | Image: Crick Institute

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post